Anika
Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to
issue its third-quarter 2014 financial results after the close of the
market on Wednesday, October 29, 2014. The company plans to hold a
conference call the next day, Thursday, October 30 at 9:00 a.m. ET to
discuss its financial results, business highlights and outlook. In
addition, the company will answer questions concerning business and
financial developments and trends, and other business and financial
matters affecting the company, some of the responses to which may
contain information that has not been previously disclosed.
To listen to the conference call, dial 855-468-0611 (international
callers dial 484-756-4332). In addition, the call will be available
through a live audio webcast in the "Investor
Relations" section of Anika’s website, www.anikatherapeutics.com.
An accompanying slide presentation also can be accessed via the Anika
Therapeutics website. The call will be archived and accessible on the
same website shortly after its conclusion.
About Anika Therapeutics, Inc.
Headquartered in Bedford, Mass., Anika
Therapeutics, Inc. develops, manufactures and commercializes
therapeutic products for tissue protection, healing, and repair. These
products are based on hyaluronic
acid (HA), a naturally occurring, biocompatible polymer found
throughout the body. Anika's products range from orthopedic/joint health
solutions led by Orthovisc®
and Monovisc®,
treatments for osteoarthritis of the knee, to surgical aids in the anti-adhesion
and ophthalmic
fields. The Company also offers aesthetic
dermal fillers for the correction of facial wrinkles. Anika's
Italian subsidiary, Anika Therapeutics S.r.l., provides complementary HA
products in orthopedic/joint health and anti-adhesion, as well as
therapeutics in areas such as advanced wound treatment and ear, nose and
throat care. Its regenerative technology advances Anika's vision to
offer therapeutic products and medical solutions that go beyond pain
relief to protect and restore damaged tissue.
Copyright Business Wire 2014